Details for Patent: 9,242,986
✉ Email this page to a colleague
Which drugs does patent 9,242,986 protect, and when does it expire?
Patent 9,242,986 protects TIVICAY PD, TRIUMEQ PD, DOVATO, JULUCA, TIVICAY, and TRIUMEQ, and is included in six NDAs.
Protection for TIVICAY PD has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty patent family members in fourteen countries.
Summary for Patent: 9,242,986
Title: | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Abstract: | A synthesis approach providing an early ring attachment via a bromination to compound 1-1 yielding compound II-II, whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q. ##STR00001## |
Inventor(s): | Kawasuji; Takashi (Osaka, JP), Nagamatsu; Daiki (Osaka, JP) |
Assignee: | SHIONOGI & CO., LTD. (Osaka, JP) ViiV Healthcare Company (Research Triangle Park, NC) |
Application Number: | 14/272,823 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,242,986 |
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 9,242,986
International Family Members for US Patent 9,242,986
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2009325128 | ⤷ Try a Trial | |||
Australia | 2014277831 | ⤷ Try a Trial | |||
Brazil | PI0923217 | ⤷ Try a Trial | |||
Canada | 2744019 | ⤷ Try a Trial | |||
Canada | 2955957 | ⤷ Try a Trial | |||
China | 102245182 | ⤷ Try a Trial | |||
European Patent Office | 2376080 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |